Climb Bio

Yahoo Finance • 2 months ago

UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences

WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team wil... Full story

Yahoo Finance • 2 months ago

Climb Bio to Present at Upcoming September 2025 Investor Conferences

WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team wil... Full story

Yahoo Finance • 4 months ago

Climb Bio appoints Cindy Driscoll as SVP Finance and principal financial officer

Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotech company with a market capitalization of $81 million, announced the appointment of Cindy Driscoll as Senior Vice President, Finance, effective June 17, 2025. According to InvestingPro... Full story

Yahoo Finance • 5 months ago

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that the Company has gran... Full story

Yahoo Finance • 6 months ago

Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX

By Exec Edge Editorial Staff Exec Edge today announced the formal launch of Exec Edge Research, a platform that will publish detailed initiation notes along with quarterly updates. Exec Edge Research is a highly specialized platform focu... Full story

Yahoo Finance • 7 months ago

Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) Completed Studies to Supp... Full story

Yahoo Finance • 8 months ago

Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished leader, with over 17 years of exper... Full story

Yahoo Finance • 8 months ago

Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

WELLESLEY, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held virtuall... Full story